Biochemical selection on conserved glycans yield a cross-species AAV capsid for efficient panretinal intravitreal delivery

Inherited retinal diseases are leading candidates for gene therapy, but photoreceptor-directed adeno-associated virus (AAV) vectors still require subretinal injection, which treats only part of the retina and carries surgical risk. Intravitreal delivery is simple and panretinal, yet inner-retinal barriers block most capsids, and capsids selected in one species rarely translate. Mapping retinal glycans across seven mammals, we found heparan sulfate (HS) marking the inner limiting membrane and terminal N-acetylglucosamine (GlcNAc) enriched on photoreceptor segments. These invariants defined a two-part design principle, attenuated HS binding with strong terminal GlcNAc engagement, implemented as a sequential in vitro selection, Conserved Receptor-Selection Technology (CReST). Its lead GlcNAc-selected capsid, AAV2.IvtB, increased retinal transgene expression 6.5-fold over AAV2.7m8 in mice and photoreceptor transduction 2.5-fold in pigs, acting through terminal GlcNAc engagement. It partially preserved photoreceptors in rd10 mice and suppressed laser-induced choroidal neovascularization. CReST is a receptor-guided, animal-free route to capsids with a defined, conserved mechanism.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.17.767272
Primary Topic
Virus-based gene therapy research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Biochemical selection on conserved glycans yield a cross-species AAV capsid for efficient panretinal intravitreal delivery

Mengtian Cui, Guangping Gao, Jun Xie, Xiao Ke et al.
bioRxiv (Cold Spring Harbor Laboratory)
Virus-based gene therapy research
preprint

Biochemical selection on conserved glycans yield a cross-species AAV capsid for efficient panretinal intravitreal delivery

Mengtian Cui, Guangping Gao, Jun Xie, Xiao Ke, Jiang-Hui Wang, Claudio Punzo, Johanna M. Seddon, Delaney Giguere, Qin Su, Ran He, Yue Yang, Wenting Zhao, Qing Xie
preprint en

Abstract

Inherited retinal diseases are leading candidates for gene therapy, but photoreceptor-directed adeno-associated virus (AAV) vectors still require subretinal injection, which treats only part of the retina and carries surgical risk. Intravitreal delivery is simple and panretinal, yet inner-retinal barriers block most capsids, and capsids selected in one species rarely translate. Mapping retinal glycans across seven mammals, we found heparan sulfate (HS) marking the inner limiting membrane and terminal N-acetylglucosamine (GlcNAc) enriched on photoreceptor segments. These invariants defined a two-part design principle, attenuated HS binding with strong terminal GlcNAc engagement, implemented as a sequential in vitro selection, Conserved Receptor-Selection Technology (CReST). Its lead GlcNAc-selected capsid, AAV2.IvtB, increased retinal transgene expression 6.5-fold over AAV2.7m8 in mice and photoreceptor transduction 2.5-fold in pigs, acting through terminal GlcNAc engagement. It partially preserved photoreceptors in rd10 mice and suppressed laser-induced choroidal neovascularization. CReST is a receptor-guided, animal-free route to capsids with a defined, conserved mechanism.

bioRxiv (Cold Spring Harbor Laboratory)
University of Massachusetts Chan Medical School (US), Centre for Eye Research Australia (AU), Chengdu Kanghong Biotech Co., Ltd. (China) (CN)
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon